Bactrim Susceptibility Against Klebsiella pneumoniae

Current Resistance Patterns and Susceptibility Data

Only 78.1% of H. influenzae isolates were susceptible to TMP-SMX at a breakpoint of 0.5 µg/mL, with even lower activity expected against K. pneumoniae 1, 2
Increasing bacterial resistance has compromised the use of co-trimoxazole, relegating it to second-line status even for traveler's diarrhea 3

For susceptible K. pneumoniae infections, third and fourth-generation cephalosporins (ceftriaxone, cefotaxime, cefepime) are recommended as first-line therapy 4
Carbapenems (ertapenem, meropenem, imipenem) offer broad-spectrum activity and are particularly valuable for ESBL-producing strains 4
Fluoroquinolones (levofloxacin, ciprofloxacin) may be used in beta-lactam allergic patients, though resistance rates are increasing 4
For carbapenem-resistant K. pneumoniae (KPC-producing), ceftazidime/avibactam or meropenem/vaborbactam are strongly recommended as first-line options 5, 6
These newer beta-lactam/beta-lactamase inhibitor combinations show superior clinical cure rates and decreased mortality compared to older regimens 5
Imipenem/relebactam and cefiderocol are conditional alternatives for KPC-producing strains 5, 6

Never use TMP-SMX as empiric therapy for serious K. pneumoniae infections without susceptibility data, as resistance rates are too high to ensure adequate coverage 3, 1
TMP-SMX is specifically NOT recommended for pediatric pneumonia caused by K. pneumoniae or other serious respiratory infections 7, 8
If culture shows TMP-SMX resistance, immediately switch to appropriate alternatives based on the resistance pattern (ESBL vs. KPC vs. fully susceptible) 4, 5
For KPC-producing strains, even if TMP-SMX susceptible, strongly consider newer agents (ceftazidime/avibactam or meropenem/vaborbactam) for serious infections given superior outcomes 5, 6

Monitor for treatment response within 48-72 hours; lack of improvement warrants culture-directed therapy adjustment 7, 8